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Abstract 
Purpose: To survey the molecular characteristics of imipenem-resistant Acinetobacter baumannii 
obtained from pediatric burns patients in a teaching hospital in Tehran, Iran. 
Methods: Over a 10-month period, 73 non-duplicate A. baumannii strains were collected from pediatric 
burns patients admitted to Motahari Burn and Reconstruction Center, Tehran, Iran. The resistance 
profile of several antimicrobials was determined. Metallo-β-lactamase (MBL)-producing isolates were 
identified using double-disk synergy and an MBL E-test. Polymerase chain reaction (PCR) was carried 
out to detect the following β-lactamase-encoding elements: blaVIM, blaIMP, blaSIM, blaSPM, blaGIM, 
blaNDM, blaAIM, blaDIM, blaKPC, blaOXA-23/24/51, and blaOXA-58. The types of integrons were also 
identified using PCR. 
Results: Out of the 73 collected strains, 92.4 and 38.3 % of the isolates were multidrug-resistant (MDR) 
and extensively drug-resistant (XDR), respectively. Colistin was the most effective antibiotic. It was 
found that 94.5 % of the strains were resistant to imipenem, as determined both by disk agar diffusion 
and MIC E-test methods. Based on double disk synergy and E-test, 78.1 and 83.5 % of the isolates, 
respectively, were MBL producers. The prevalence of blaOXA-23 and blaOXA-24 were 75.4 and 39.1 
%, respectively. The results also indicate that 62.3, 30.4, and 4.3 % of the isolates were positive for 
blaVIM, blaIMP and blaNDM genes, respectively. Furthermore, 16.4, 76.1, and 7.5 % of the isolates 
carried intI, intII, and intIII genes, respectively.  
Conclusion: The increased frequency of carbapenem-resistant A. baumannii in burns cases underlines 
the importance of choosing an appropriate antibacterial regimen based on antibiotic susceptibility 
profile. Rapid identification of carbapenemase-producing strains would be helpful for selecting suitable 
antimicrobial therapy and preventing further spread of their encoding genes. 
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INTRODUCTION 
 
Burn wound infections are significant causes of 
morbidity and mortality, and they are ultimately 
responsible for 50 – 75 % of deaths. 
Acinetobacter baumannii is widely dispersed as 
an important opportunistic pathogen, especially 
in burn patients, all over the world [1]. Increasing 
resistance in this bacterium complicates the 
selection of suitable empirical therapy in severe 
infections, such as burn wound injuries. The 
carbapenems are broadly regarded as a suitable 
option for the treatment of severe infections 
caused by multidrug-resistant A. baumannii (MR-
AB) [2]. In the low-income countries, the 
incidence of carbapenem-resistant A. baumannii 
(CR-AB) infections is increasing at an alarming 
rate, especially among hospitalized burn patients 
[3].  
Carbapenem resistance in A. baumannii is 
related to several combined mechanisms, such 
as the acquisition of β-lactamases, AmpC stable 
derepression, low outer membrane permeability, 
altered penicillin-binding proteins (PBPs), and 
less frequently, efflux pump overexpression [4]. 
Especially, oxacillinase (OXA)-type β-lactamases 
(Ambler class D enzymes) and metallo-β-
lactamases (MBL; Ambler class B enzymes) 
have been identified worldwide from CR-AB 
strains. MBL enzymes, including IMP, VIM, SPM, 
GIM, SIM, AIM, FIM, and NDM, are zinc-
dependent carbapenemases; they are inhibited 
by EDTA and play a crucial role in drug 
resistance against carbapenems. OXAs, which 
are not inhibited by EDTA and/or clavulanic acid, 
are subdivided into six families, as follows: the 
OXA-23-like, OXA-24/40-like, OXA-51-like, OXA-
58-like, OXA-143-like, and OXA-182-like families 
[4,5].  
 
Carbapenemases have a high ability to spread, 
since their encoding genes have usually been 
found in transferable plasmids comprising 
integrons and insertion sequence (IS) 
determinants. Integrons are assembly genetic 
platforms/DNA segments that can gain gene 
cassettes carrying antibiotic-resistance elements 
via a site-specific recombination. These genetic 
elements are recognized by the presence of 
three essential apparatuses for producing 
exogenous genes, as follows: an integrase (intI 
gene), attI (a recombination site), and PC (a 
promoter). The most common types of integrons 
are transportable class I, followed by class II and 
III integrons [3,6]. In recent years, A. baumannii 
strains producing MBL-, OXA-, and KPC-type 
carbapenemases have been increasingly found 
in Iran [2]. This study was performed to 
determine the antibiotic resistance profiles and 
frequencies of MBL-, OXA-, and KPC-encoding 
determinants and int genes in A. baumannii 
isolated from pediatric burn patients in Tehran, 
Iran. 
 
EXPERIMENTAL 
 
Ethical approval 
 
The study was approved by the ethical 
committee of Iran University of Medical Sciences 
(IUMS), Tehran, Iran (consent ref no. 
IR.IUMS.REC 1395.9221133207). Written 
informed consent form was collected from the 
patients or a close relative. Identifying 
information of each sample was kept secret. 
Each  stage  of  sampling  was done  in  such  a  
way  as  to  minimize  pain  and harm to the 
patients and international guidelines for human 
studies were followed [7]. 
 
Sampling and bacterial isolates 
 
This cross-sectional study was performed on 
patients hospitalized at the pediatric ward of the 
Motahari Burn and Reconstruction Center in 
Tehran, Iran, from October 2016 to June 2017. 
The Motahari burn hospital is one of the 
specialized burn centers in our country, providing 
care to burn cases from Tehran (the capital of 
Iran) and patients with complications who have 
been referred from other therapeutic centers 
across the country. The hospital currently 
operates under the Iran University of Medical 
Sciences (IUMS). Burns patients were recruited 
according as per Bowler et al [1]. A. baumannii 
was initially identified using biochemical and 
microbiological procedures and then, confirmed 
using an API 20 NE Kit (version 6.0, bioMérieux, 
Marcy l’Étoile, France). Each isolate was 
preserved in Luria–Bertani broth (Merck Co., 
Germany) containing 20 % glycerol (v/v) at –80 
°C for further use. A. baumannii ATCC 19606 
was used as a quality control. 
 
Antimicrobial susceptibility testing 
 
An antimicrobial susceptibility test was 
conducted using the disk agar diffusion (DAD) 
assay, as suggested by the Clinical and 
Laboratory Standards Institute (CLSI document 
M100-S14) [8], on Mueller–Hinton agar (MHA) 
plates for the 11 following antimicrobials: 
levofloxacin (LEV; 5 µg); ceftazidime (CAZ; 30 
µg), cefotaxime (CTX; 30 µg), 
piperacillin/tazobactam (TZP; 100/10 µg), 
imipenem (IPM; 10 µg), ciprofloxacin (CIP; 5 µg), 
tobramycin (TOB; 10 μg), gentamicin (GM; 10 
µg), piperacillin (PIP; 100 µg), tetracycline (TET; 
30 µg), and trimethoprim-sulfamethoxazole 
(SXT; 5 µg; MAST Diagnostics, Merseyside, UK). 
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Multidrug-resistant (MDR), extensively drug-
resistant (XDR), and pan-drug-resistant (PDR) 
isolates were identified based on the guidelines 
suggested by the Centers for Disease Control 
and Prevention (CDC). Each strain was tested 
for colistin (CL) and IPM susceptibility using an 
E-test in line with the manufacturer’s guidelines 
(Liofilchem SRL, Roseto degli Abruzzi, Italy). The 
Liofilchem MIC Test Strips (MTS) for colistin (CS; 
drug concentration gradient of 0.016 – 256 
mg/ml, with interpretative criteria of susceptible 
[S], ≤ 2 μg/ml, resistant [R], ≥ 4 μg/ml) and IPM 
(range: 0.002 – 32 µg/ml, MIC interpretative 
criteria of S, ≤ 4 µg/ml, R, ≥ 16 µg/ml) were used. 
The strips were placed onto MHA medium with 
an added bacterial suspension equal to 0.5 
McFarland. After incubation at 37 °C for 18 – 24 
h, E-test MICs were determined as the point of 
interception of the zone of inhibited growth with 
the strips. 
 
Identification of the MBL phenotype 
 
For the identification of MBL-producing isolates, 
a combined disk diffusion test (CDDT) was 
performed. Concisely, a 0.5 McFarland turbidity 
of the bacterial suspension was streaked on an 
MHA plate. Then, two 10-μg IPM disks were 
placed on the MHA plates; following this, 10 μL 
of MBL inhibitor solution (0.5 M EDTA) was 
added to one of the IPM disks to reach a desired 
concentration of 750 mg. After 24 h of incubation 
at 35 °C, the inhibition zone diameters of all 
disks were recorded and compared. The isolates 
were considered MBL-producing isolates when 
the difference in the inhibition zones was 
observed to be ≥ 7 mm. In addition, MBL E-test 
MIC values (IPM [range: 4 – 256 μg/mL] and 
IPM/EDTA [IMD; range: 1 – 64 μg/mL]; 
Liofilchem SRL) was done according to the 
company’s instructions. An IPM/IMD ratio ≥ 8 
μg/L was considered positive. 
 
Modified hodge test (MHT) 
 
The Modified Hodge test (MHT) was performed 
in all IPM-resistant isolates according to the CLSI 
guideline to identify carbapenemase-producing 
organisms. An overnight suspension of 
Escherichia coli ATCC 25922 equivalent to the 
turbidity of the 0.5 McFarland standard was 
streaked on MHA using a sterile cotton swab. 
Then, a 10-μg meropenem disk (HI-MEDIA, 
Mumbai, India) was placed at the center of the 
petri dish, and the test isolate was cultured from 
the edge of the disk to the margin of the plate in 
four orders. The presence of a 'cloverleaf-
shaped' inhibition zone after 24 h incubation at 
37 °C was considered as a positive test result. 
 
Polymerase chain reaction (PCR)  
 
A DNA Extraction Kit (Bioneer Company, Korea, 
Cat. number K-3032-2) was used to extract 
genomic DNA from the colonies grown overnight 
in brain heart infusion agar plates. The 
concentration and quality of the total genomic 
DNA extracted were evaluated using a 
NanoDrop™ 1000 Spectrophotometer (Thermo 
Scientiﬁc, Wilmington, DE, USA). DNA isolates 
with a concentration of 0.1 ng/µl were used as 
the templates for polymerase chain reaction 
(PCR) assay. The oligonucleotide primer 
sequences used for amplification of target genes, 
including blaVIM, blaIMP, blaSIM, blaSPM, blaGIM, 
blaNDM, blaAIM, blaDIM, blaKPC, blaOXA-23/24/51/58 and 
int are recorded in Table 1. The PCR mixture 
was carried out in a final volume of 25 μl, 
including the following ingredients: 0.5 µl of 
bacterial DNA extract; 2 µl of 10 × PCR buffer; 
1.8 mmol/l of MgCl2; 0.8 µl (each) of dATP, 
dGTP, dCTP, and dTTP; 0.7 µl of each primer; 
0.8 µl of Taq DNA polymerase (5 U/µl; Amplicon 
Co., Denmark); and 15.3 µl of ddH2O. The genes 
were amplified in a Techne TC-512 thermocycler 
(Eppendorf, Hamburg-Nord, Germany), as 
follows: initial denaturation at 95 °C for 3 min, 35 
cycles of denaturation for 50 s at 95 °C, 
annealing for 40 s at 55 °C, and extension for 
120 s at 72 °C, as well as a final extension for 5 
min at 72 °C. PCR amplicons were subjected to 
electrophoresis in a 1.5 % agarose gel for 2 h at 
70 V with a 100-bp size marker (Fermentas Co., 
Lithuania), stained with Gel Red™ (Biotium, 
USA), and photographed with ultraviolet 
illumination (Bio-rad, Hercules, USA). 
 
RESULTS 
 
In general, 73 non-duplicative burned wound 
samples were collected from the patients (n = 41, 
56.2 % female; n = 32, 43.8 % male). The mean 
age of the patients studied was 8.5 years, with a 
range of 4 – 17 years. The antimicrobial 
susceptibility results are shown in Table 2. The 
frequencies of MDR and XDR isolates were 92.4 
and 38.3 %, respectively. Moreover, 94.5 % (n = 
69/73) of the strains were resistant to IPM, as 
determined by both the DAD and MIC E-test 
methods. The results of the E-test showed that 
CL was the most effective antimicrobial, with a 
susceptibility rate of 98.6 %. Only 1.4 % (n = 1) 
of the isolates were resistant to CL in the MTS 
with the interpretative criterion of ≥ 4 μg/ml. 
Among the 69 IPM-resistant A. baumannii, 82.6 
% (n = 57) and 88.4 % (n = 61) were MBL 
producers, as determined by the CDDT and E-
test methods, respectively. 
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Table 1: Oligonucleotide primer sequences used in this study 
 
Target gene Primer sequence (5ʹ→3ʹ) Product size (bp) Reference 
intI F=5ʹ-GGTGTGGCGGGCTTCGTG-3ʹ 
R=5ʹ-GCATCCTCGGTTTTCTGG-3ʹ 
457  [9] 
intII F=5ʹCACGGATATGCGACAAAAAGGT -3ʹ 
R=5ʹ-GTAGCAAACGAGTGACGAAATG -3ʹ 
789 
intIII F=5ʹ-GCCTCCGGCAGCGACTTTCAG -3ʹ 
R=5ʹ-ACGGATCTGCCAAACCTGACT -3ʹ 
980 
IMP F=5ʹ- TGAGCAAGTTATCTGTATTC-3ʹ  
R=5ʹ- TTAGTTGCTTGGTTTTGATG-3ʹ  
740 [10] 
SPM F=5ʹ- CCTACAATCTAACGGCGACC-3ʹ  
R=5ʹ- TCGCCGTGTCCAGGTATAAC-3ʹ  
674 
VIM F=5ʹ- AAAGTTATGCCGCACTCACC-3ʹ  
R=5ʹ- TGCAACTTCATGTTATGCCG-3ʹ  
815 
NDM F=5ʹ- GGTTTGGCGATCTGGTTTTC-3ʹ 
R=5ʹ- CGGAATGGCTCATCACGATC-3ʹ 
627 [11] 
DIM F=5ʹ- GCTTGTCTTCGCTTGCTAACG-3ʹ 
R=5ʹ- CGTTCGGCTGGATTGATTTG-3ʹ 
699 [12] 
AIM F=5ʹ- CTGAAGGTGTACGGAAACAC-3ʹ 
R=5ʹ- GTTCGGCCACCTCGAATTG-3ʹ 
322 
GIM F=5ʹ- TCGACACACCTTGGTCTGAA-3ʹ 
R=5ʹ- AACTTCCAACTTTGCCATGC-3ʹ 
477 
SIM F=5ʹ-  TACAAGGGATTCGGCATCG-3ʹ 
R=5ʹ- TAATGGCCTGTTCCCATGTG-3ʹ 
570 
OXA-23-like F=5ʹ- GATCGGATTGGAGAACCAGA-3ʹ 
R=5ʹ- ATTTCTGACCGCATTTCCAT-3ʹ 
501 [11] 
OXA-24-like F=5ʹ- GGTTAGTTGGCCCCCTTAAA-3ʹ 
R=5ʹ- AGTTGAGCGAAAAGGGGATT-3ʹ 
246 
OXA-85-like F=5ʹ- AAGTATTGGGGCTTGTGCTG-3ʹ 
R=5ʹ- CCCCTCTGCGCTCTACATAC-3ʹ 
599 
OXA-51-like F=5ʹ- TAATGCTTTGATCGGCCTTG-3ʹ 
F=5ʹ- TGG ATTGCACTTCATCTTGG-3ʹ 
353 [13] 
KPC F=5ʹ- CTTGCTGCCGCTGTGCTG -3ʹ  
R=5ʹ- GCAGGTTCCGGTTTTGTCTC -3ʹ 
489 
 
MBL genes detected in this study were blaVIM (n 
= 43, 62.3 %), blaIMP (n = 21, 30.4 %), and blaNDM 
(n = 3, 4.3 %). The coexistence of blaIMP and 
blaVIM was observed in 10.4 % of isolates (n = 
7/69). Only 4.3 % (n = 3/69) of IPM-resistant A. 
baumannii were negative for MBL activity and the 
genes tested. No amplicons were obtained with 
the primer detecting the blaDIM, blaSIM, blaAIM, and 
blaSPM genes. 
 
In this study, all isolates harbored the blaOXA-51-like 
gene, intrinsic to A. baumannii strains. Out of 69 
CR-AB isolates, 75.4 % (n = 52) and 39.1 % (n = 
27) were found to harbor the blaOXA-23-like and 
blaOXA-24-like genes, respectively. The coexistence 
of the blaOXA-23-like and blaOXA-24-like genes occurred 
in 17.4 % (n = 12/69) of isolates. No isolates 
were positive for the blaOXA-58-like gene.  
 
In the MHT, 13 % (n = 9/69) of the strains were 
positively identified as KPC-producing isolates, 
as they developed a cloverleaf shape; however, 
only 5.8 % (n = 4/69) of isolates carried the 
blaKPC gene. The Int gene was found in 91.7 % (n 
= 67/73) of the isolates.  
 
The molecular analyses of class I, II, and III 
integrons showed that 16.4 % (n = 11/67), 76.1 
% (n = 51/67), and 7.5 % (n = 5/67) of the strains 
harbored the intI, intII, and intIII genes, 
respectively. The coexistence of intI/intII and 
intI/intII/intIII in isolates were 11.9 % (n = 8) and 
2.9 % (n = 2), respectively. 
 
 
Table 2: Antimicrobial susceptibility profile of A. 
baumannii isolates 
 
Antimicrobial 
agent 
Antimicrobial susceptibility, N 
(%)  
S I R 
TZP 1 (1.4) 0 (0.0) 72 (98.6) 
CIP 0 (0.0) 0 (0.0) 73 (100) 
CTX 0 (0.0) 0 (0.0) 73 (100) 
CAZ 2 (2.7) 0 (0.0) 71 (97.3) 
IPM 4 (5.5) 0 (0.0) 69 (94.5) 
PIP 0 (0.0) 0 (0.0) 73 (100) 
TOB 1 (1.4) 1 (1.4) 71 (97.3) 
TET 3 (4.1) 0 (0.0) 70 (95.9) 
GM 2 (2.7) 1 (1.4) 70 (95.9) 
LEV 1 (1.4) 0 (0.0) 72 (98.6) 
SXT 0 (0.0) 0 (0.0) 73 (100) 
LEV; levofloxacin, CAZ; ceftazidime, CTX; cefotaxime, 
TZP; piperacillin/tazobactam, PIP; Piperacillin, IPM; 
imipenem, CIP; ciprofloxacin, TOB; Tobramycin, GM; 
gentamicin, TET; tetracycline, SXT trimethoprim-
sulphamethoxazole, S; susceptible, I; intermediate, R; 
resistant 
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Figure 1: Distribution of genes encoding carbapenemases and integrase in A. baumannii isolated from pediatric 
burns patients. 
 
DISCUSSION 
 
The rapid emergence of MDR-AB and XDR-AB 
strains in recent years has become an important 
concern for treatment of hospital acquired 
infections, especially in burn patients [7]. The 
results of this study, which supported the findings 
of other studies [14,15], revealed the presence of 
A. baumannii strains with multiple resistances to 
antimicrobials in our hospital. Furthermore, we 
found a high resistance rate to carbapenems 
(94.5 %), a class of antibiotics that used to be the 
drug of choice. Similarly, Shoja et al [11] showed 
that 92.5 % of A. baumannii isolated from burn 
patients were resistant to carbapenems, and 
therefore, these agents are not suitable for the 
treatment of infections.  
 
Polymyxins, such as CL, are effective agents 
against the overwhelming majority of A. 
baumannii throughout the world. In a systematic 
review study conducted by Razavi et al [16], 
polymyxins showed adequate activity against A. 
baumannii isolated from 2006 to 2013; in their 
results, 77 – 100 % of isolates were susceptible 
to CL. Furthermore, they found no significant 
change in the resistance of isolates to this 
antibiotic during the study period. Similarly, we 
found that 98.6 % of isolates were susceptible to 
CL. These findings indicate that CL has 
increasingly become the last viable therapeutic 
choice for MDR-AB infections. 
 
It has been suggested that OXA-type 
carbapenemases play an important role in 
carbapenem resistance in A. baumannii. 
Outbreaks of CR-AB harboring the blaOXA-23-like 
gene occurs in 31 % to 100 % worldwide [12]. 
The prevalence of the blaOXA-23-like and blaOXA-24-
like genes in the current study were 75.4 and 39.1 
%, respectively. Quiñones et al [17] showed that 
75 % of CR-AB isolates harbored different blaOXA 
genes (blaOXA-23: 73 %, blaOXA-24: 18 %, blaOXA-58: 
3 %), which suggests that these OXAs may be 
locally spread. Moreover, Farshadzadeh et al 
[18] showed that the broad distribution of the 
blaOXA-23-like gene was the main reason for the 
rapid increase in the carbapenem resistance rate 
among burn patients in Iran.  
 
It has been reported that when screening for 
carbapenemases, two confounders must be 
ruled out, as follows: (i) not all carbapenem-
resistant strains produce a carbapenemase, and 
(ii) not all carbapenemase producers are 
resistant to carbapenems [19]. The carbapenem-
resistant strains in this study were screened 
using the MHT and IMD methods, which have 
been effectively used to validate carbapenemase 
producers. These tests can also discriminate 
carbapenem-resistance mediated by 
carbapenemases from that mediated by other 
mechanisms. The present study showed that 
carbapenem-resistance was chiefly caused by 
MBLs. However, the observed low rates of 
carbapenemase activity in MHT among CR-AB 
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could have emerged because the identification of 
carbapenemase activity in clinical strains is 
challenging [20]; the MHT method suffers from 
low sensitivity, and interpretation of its results 
can be subjective (the cloverleaf indentation). 
Thirteen percent of KPC-producing isolates were 
found phenotypically, but only 5.8 % of isolates 
were positive for the blaKPC gene. This contrast 
may have been due to reduced susceptibility to 
at least one extended-spectrum cephalosporin 
and another mechanism, such as carbapenem 
resistance due to a combination of an extended-
spectrum beta-lactamases (ESBLs) or AmpC-
type enzyme with porin loss [21].  
 
In the present study, blaVIM was the most 
prevalent MBL-encoding gene tested (62.3 %), 
followed by blaIMP (30.4 %) and blaNDM (4.3 %). In 
a study performed by Fallah et al [22], 17.4 and 
3.5 % of A. baumannii isolates were positive for 
the blaVIM and blaIMP genes, respectively. Yousefi 
et al [9] showed that blaIMP was more important, 
especially among the clinical isolates of 
Pseudomonas aeruginosa in Iran. Regarding the 
relatively high frequency of blaNDM in our study, it 
is important to note that blaNDM was primarily 
recognized in India, and only later was it reported 
from other countries, such as Pakistan. The 
proximity of these countries to Iran and the large 
number of visits and immigration between the 
states on the one hand and the ease of 
resistance transfer among the organisms on the 
other led us to think that it may be feasible for 
our strains to have a similar gene. In 
concordance with Fallah et al [22], these studies 
are valuable for preventing the spread of 
resistant organisms to other parts of the world. 
 
In this work, 91.7 % of A. baumannii isolates 
carried genes encoding integrase, a necessary 
element for integron functions. Our results 
showed that class II integron was the most 
prevalent in our isolates, which agreed with the 
results of Deylam Salehi et al [14] and Mirnejad 
et al [23], but contrasted with the reports of Lin et 
al [24] and Taherikalani et al [15]. Chen et al [25] 
showed that detection of integrons is an indicator 
for evaluating MDR-AB epidemics. The 
differences in the prevalence of integron types in 
previous studies and the present one are most 
likely owing to the geographical distance, 
surveillance strategies, and restraint in antibiotic 
prescriptions in other regions. 
 
CONCLUSION 
 
The findings of this study demonstrate a high 
prevalence of CR-AB isolates that carry various 
encoding genes and could produce 
carbapenemases at the study site. Rapid and 
precise identification of these strains is 
necessary for selection of suitable antimicrobial 
therapy, controlling their inter- or intra-hospital 
spread, and ultimately, diminishing related 
infections, especially in burn patients. 
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